Search fresh public links, source activity, and post angles for Alida Biosciences.
Fresh curated links around Alida Biosciences are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
After emerging from stealth last month with $175 million in funding, Korsana Biosciences has wasted no time making its way to the public markets.
Backed by OrbiMed, Novartis’ venture arm and many other investors, the biotech is among those working on newer technology that could broaden the reach of antibody-drug conjugates.
Californian protein sequencing company Alamar Biosciences is seeking an IPO worth up to $159 million amid a growing boom in life sciences public offerings.
Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) tr...
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior versions of entrenched — but flawed — medicines for idio...
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
The agreement allows Biogen to apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for...
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological dise...
Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather than pursue the phase 3 program envisaged before it acquir...
Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.
Revolution Medicines Anonymous (not verified) Tue, 05/05/2026 - 02:20 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...
Image source: The Motley Fool. DATEThursday, May 7, 2026 at 8 a.m. ETCALL PARTICIPANTSCo-Chief Executive Officer — Justin KleeCo-Chief Executive Officer — Joshua CohenChief Commer...
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based...
RNA sequencing now enables simultaneous detection of multiple RNA modifications alongside gene expression, providing deeper...
What You Should Know Lucent Diagnostics (a brand of Quanterix) and Tempus AI have announced a strategic collaboration to integrate Alzheimer’s blood-based biomarker testing into ro...
Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fat...
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch of new investors. The San Diego startup has sunk its t...
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with metabolic dysfunction-associated steato...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.